Andrew B. Nixon

7.5k citations

168 papers · 5.6k indexed · 1 hit paper · h-index 33

Oncology top 1%
- Colorectal Cancer Treatments and Studies 39
- Cancer Treatment and Pharmacology 18
- Cancer Immunotherapy and Biomarkers 14
Molecular Biology top 2%
- Angiogenesis and VEGF in Cancer 20
Cancer Research top 2%
- Cancer Genomics and Diagnostics 18
Immunology top 5%
Cell Biology top 5%
Pulmonary and Respiratory Medicine
- Lung Cancer Treatments and Mutations 21
- Renal cell carcinoma treatment 14
Pathology and Forensic Medicine
- Genetic factors in colorectal cancer 17

Co-authors: Akihiro Ito Charlotte Hubbert Rong Shao Tso‐Pang Yao Xiao‐Fan Wang Yoshiharu Kawaguchi Minoru Yoshida Amaris R. Guardiola
Cited by: Oncology Molecular Biology Cancer Research
Journals: Nature (1 paper)Journal of Biological Chemistry (6 papers)Journal of Clinical Investigation (3 papers)
Partner nations: United States Canada United Kingdom

In The Last Decade

Andrew B. Nixon

156 papers receiving 5.5k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Andrew B. Nixon

Since Specialization

Citations

This map shows the geographic impact of Andrew B. Nixon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew B. Nixon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew B. Nixon more than expected).

Fields of papers citing papers by Andrew B. Nixon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew B. Nixon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew B. Nixon. The network helps show where Andrew B. Nixon may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Andrew B. Nixon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Andrew B. Nixon Line = papers co-authored together Andrew B. Nixon links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial Nature Communications ·Jeffrey Clarke,George R. Simon,Hirva Mamdani,Lin Gu,James E. Herndon,Thomas E. Stinchcombe,Neal Ready,Jeffrey Crawford,Guru Sonpavde,Stephen J. Balevic,Andrew B. Nixon,Michael J. Campa,Elizabeth B. Gottlin,Huihua Li,Ruchi Saxena,You‐Wen He,Scott Antonia,Edward F. Patz	2025	7
2	Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202) Journal of Clinical Oncology ·Emily K. Bergsland,Susan Geyer,Timothy R. Asmis,Spencer C. Behr,J. Philip Kuebler,Priya Kumthekar,Gina L. Mazza,Michael L. Maitland,Donna Niedzwiecki,Andrew B. Nixon,Lawrence H. Schwartz,Jonathan Strosberg,Alan P. Venook,Eileen M. O’Reilly,Jeffrey A. Meyerhardt	2025	0
3	Circulating Angiokines Are Associated With Reverse Remodeling and Outcomes in Chronic Heart Failure Journal of Cardiac Failure ·Josephine Harrington,Andrew B. Nixon,Melissa A. Daubert,Eric Yow,James L. Januzzi,Mona Fiuzat,David J. Whellan,Christopher M. O’Connor,Justin A. Ezekowitz,Ileana L. Piña,Kirkwood F. Adams,G. Michael Felker,Ravi Karra	2023	5
4	Evaluating immune response and metabolic related biomarkers pre-allogenic hematopoietic stem cell transplant in acute myeloid leukemia PLoS ONE ·Sharareh Siamakpour‐Reihani,Felicia Cao,Jing Lyu,Yi Ren,Andrew B. Nixon,Jichun Xie,Amy Bush,Mark D. Starr,James R. Bain,Michael J. Muehlbauer,Olga Ilkayeva,Virginia B. Kraus,Janet L. Huebner,Nelson J. Chao,Anthony D. Sung	2022	0
5	Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma Clinical Cancer Research ·Andrew J. Armstrong,Andrew B. Nixon,Andrea Carmack,Qian Yang,Tim Eisen,Walter M. Stadler,Robert J. Jones,Jorge A. García,Ulka N. Vaishampayan,Joel Picus,Robert E. Hawkins,John D. Hainsworth,Christian Kollmannsberger,Theodore F. Logan,Igor Puzanov,Lisa Pickering,Christopher W. Ryan,Andrew Protheroe,Daniel J. George,Susan Halabi	2021	18
6	Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study Clinical Cancer Research ·Erika J. Lampert,Alexandra S. Zimmer,Michelle R. Padget,Ashley Cimino‐Mathews,Jayakumar R. Nair,Yingmiao Liu,Elizabeth M. Swisher,James W. Hodge,Andrew B. Nixon,E. Hitt Nichols,Mohammadhadi Bagheri,Elliott Levy,Marc R. Radke,Stanley Lipkowitz,Christina M. Annunziata,Janis M. Taube,Seth M. Steinberg,Jung‐Min Lee	2020	150
7	Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy Clinical Cancer Research ·Mark J.A. Schoonderwoerd,Maaike F.M. Koops,Ricardo A. Angela,Bryan Koolmoes,Melpomeni Toitou,Madelon Paauwe,Marieke C. Barnhoorn,Yingmiao Liu,Cornelis F.M. Sier,James C.H. Hardwick,Andrew B. Nixon,Charles P. Theuer,Marieke F. Fransen,Lukas J.A.C. Hawinkels	2020	37
8	Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib Molecular Cancer Therapeutics ·Yingmiao Liu,Jing Lyu,Kirsten B. Burdett,Alexander B. Sibley,Ace J. Hatch,Mark D. Starr,John C. Brady,Kelli Hammond,Federica Marmorino,Daniele Rossini,Richard M. Goldberg,Alfredo Falcone,Chiara Cremolini,Kouros Owzar,Anastasia Ivanova,Dominic T. Moore,Michael S. Lee,Hanna K. Sanoff,Federico Innocenti,Andrew B. Nixon	2020	15
9	A multi‐institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer Cancer ·Richard D. Kim,Hanna K. Sanoff,Andrew Poklepovic,Heloisa P. Soares,Jongphil Kim,Jing Lyu,Yingmiao Liu,Andrew B. Nixon,Dae Won Kim	2020	34
10	P-131 Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma: Interim analysis of a phase II trial Annals of Oncology ·H. Park,Aravind Sanjeevaiah,Rama Suresh,Rutika Mehta,Nikolaos A. Trikalinos,Nusayba A. Bagegni,Olivia Aranha,Katrina S. Pedersen,Andrew B. Nixon,Ramon U. Jin,Jason C. Mills,Ryan C. Fields,Manik Amin,Kian‐Huat Lim,Benjamin Tan,Patrick Grierson,Shu Jiang,Maximillian Rosario,Andrea Wang‐Gillam,A. Craig Lockhart	2020	1
11	A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors Cancer Chemotherapy and Pharmacology ·Niharika B. Mettu,Donna Niedzwiecki,Christel Rushing,Andrew B. Nixon,Jingquan Jia,Sherri Haley,Wanda Honeycutt,Herbert I. Hurwitz,Johanna C. Bendell,Hope E. Uronis	2019	7
12	Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105 Molecular Cancer Therapeutics ·Yingmiao Liu,Mark D. Starr,John C. Brady,Christel Rushing,Herbert Pang,Bonne J. Adams,Delia Alvarez,Charles P. Theuer,Herbert I. Hurwitz,Andrew B. Nixon	2018	15
13	Biomarker Signatures Correlate with Clinical Outcome in Refractory Metastatic Colorectal Cancer Patients Receiving Bevacizumab and Everolimus Molecular Cancer Therapeutics ·Yingmiao Liu,Mark D. Starr,John C. Brady,Christel Rushing,Anuradha Bulusu,Herbert Pang,Wanda Honeycutt,Anthony Amara,Ivy Altomare,Hope E. Uronis,Herbert I. Hurwitz,Andrew B. Nixon	2015	18
14	Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing Clinical Cancer Research ·Jingquan Jia,Andrew Dellinger,Eric S. Weiss,Anuradha Bulusu,Christel Rushing,Haiyan Li,Leigh A. Howard,Neal Kaplan,Herbert Pang,Herbert I. Hurwitz,Andrew B. Nixon	2015	4
15	Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results from CALGB 80203 (Alliance) Clinical Cancer Research ·Stephanie M. Cushman,Chen Jiang,Ace J. Hatch,Ivo Shterev,Alexander B. Sibley,Donna Niedzwiecki,Alan P. Venook,Kouros Owzar,Herbert I. Hurwitz,Andrew B. Nixon	2014	66
16	Ectodomain shedding of TβRIII is required for TβRIII-mediated suppression of TGF-β signaling and breast cancer migration and invasion Molecular Biology of the Cell ·Jennifer Elderbroom,Jennifer J. Huang,Catherine E. Gatza,Jian Chen,Tam How,Mark D. Starr,Andrew B. Nixon,Gerard C. Blobe	2014	38
17	A Phase Ib Study of Combined VEGFR and mTOR Inhibition With Vatalanib and Everolimus in Patients With Advanced Renal Cell Carcinoma Clinical Genitourinary Cancer ·Rhonda L. Bitting,Patrick Healy,Patricia Creel,James Turnbull,Karla K. Morris,Sarah Yenser Wood,Herbert I. Hurwitz,Mark D. Starr,Andrew B. Nixon,Andrew J. Armstrong,Daniel J. George	2013	24
18	Regulation of platelet-activating factor synthesis in human neutrophils by MAP kinases Biochimica et Biophysica Acta (BBA) - Molecular Cell Research ·Paul R.S. Baker,J.S. Owen,Andrew B. Nixon,Leslie N Thomas,Rhonda E. Wooten,Larry W. Daniel,Joseph T. O’Flaherty,Robert L. Wykle	2002	27
19	Comparison of acceptor and donor substrates in the CoA-independent transacylate reaction in human neutrophils Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism ·Andrew B. Nixon,D G Greene,Robert L. Wykle	1996	6
20	A facile synthesis of 1-O-alkyl-2-(R)-hydroxypropane-3-phosphonocholine (lyso-phosphono-platelet activating factor) Chemistry and Physics of Lipids ·Jeffrey D. Schmitt,Andrew B. Nixon,Adalsteinn Emilsson,Larry W. Daniel,Robert L. Wykle	1992	6

About Andrew B. Nixon

Andrew B. Nixon is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 168 papers that have together received 5.6k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (39 papers), Lung Cancer Treatments and Mutations (21 papers), Angiogenesis and VEGF in Cancer (20 papers), Cancer Genomics and Diagnostics (18 papers), Cancer Treatment and Pharmacology (18 papers), Genetic factors in colorectal cancer (17 papers), Renal cell carcinoma treatment (14 papers) and Cancer Immunotherapy and Biomarkers (14 papers). The work is most often cited by research in Oncology (2.2k citations), Molecular Biology (3.3k citations) and Cancer Research (685 citations). Andrew B. Nixon has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Akihiro Ito, Charlotte Hubbert, Rong Shao, Tso‐Pang Yao, Xiao‐Fan Wang, Yoshiharu Kawaguchi, Minoru Yoshida, Amaris R. Guardiola, Herbert I. Hurwitz and Mark D. Starr. Their work appears in journals such as Nature, Journal of Biological Chemistry and Journal of Clinical Investigation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact